VOYDEYA Sales Forecast, and Market Size Analysis – 2034

Key Factors Driving VOYDEYA Growth

1. Strategic Approvals and Regulatory Successes

VOYDEYA has received approvals in major regions:

• Japan: First regulatory approval for adults with PNH, in combination with C5 inhibitors, based on the pivotal ALPHA Phase III trial.
• United States: FDA approved VOYDEYA as an add-on therapy for PNH patients experiencing EVH despite standard therapy.
• European Union: The European Commission approved VOYDEYA as an add-on to ravulizumab or eculizumab for adults with PNH who have residual hemolytic anemia.

These approvals, supported by orphan drug status, Breakthrough Therapy designation (FDA), and PRIME status (EMA), have significantly lowered development risks and sped regulatory review.

2. Strong ALPHA Phase III Trial Data Supporting Clinical Value

The ALPHA Phase III trial demonstrated clinically meaningful benefits for VOYDEYA as add-on treatment with standard C5 inhibitors:

• Clinically meaningful increases in hemoglobin levels (LSM ~2.9 g/dL) compared with placebo at Week 12.
• Increased rates of transfusion avoidance (~83.3 % of patients with VOYDEYA add-on vs 38.1 % on placebo).
• Long-term extension (up to ~72 weeks) showed sustained improvements in hemoglobin, transfusion avoidance, and fatigue scores.

These functional benefits address a previously unmet component of PNH care (EVH), validating VOYDEYA’S complementary mechanism to existing therapies and supporting its clinical adoption.

3. Differentiated Mechanism in Complement Inhibition

VOYDEYA’S mechanism — blocking Factor D in the alternative pathway of the complement system — is unique compared with traditional C5 inhibitors (SOLIRIS, ULTOMIRIS). This means it targets a different part of the complement cascade, addressing extravascular hemolysis while co-administered C5 inhibition continues to control intravascular hemolysis.

By offering dual pathway management (Factor D + C5), VOYDEYA helps treat the subset of PNH patients who otherwise remain symptomatic with existing therapy alone.

4. Addressing an Unmet Niche Within a Rare Disease Population

Even though PNH is rare, the PNH treatment market is projected to expand significantly:

A PNH treatment market report valued the segment at roughly US $5 billion in 2025, with expectations to reach ~US $13.9 billion by 2035 (≈10.8 % CAGR), driven by innovations in complement inhibitors and increased therapeutic options.

5. Pipeline Expansion Potential Beyond PNH

AstraZeneca is exploring VOYDEYA in additional indications, such as geographic atrophy, a progressive eye disease related to complement dysregulation, with ongoing Phase II research. While this is early stage, it broadens the potential long-term utilization beyond PNH.

VOYDEYA Recent Developments

In January 2024, VOYDEYA (Danicopan) had been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of patients (approximately 10-20%) with PNH who experience clinically significant extravascular haemolysis (EVH) while treated with a C5 inhibitor.

The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.

“VOYDEYA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of VOYDEYA for approved indication like Paroxysmal nocturnal haemoglobinuria; as well as potential indications like Chronic urticaria and Dry macular degeneration in the 7MM. A detailed picture of VOYDEYA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the VOYDEYA for approved and potential indications. The VOYDEYA market report provides insights about VOYDEYA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current VOYDEYA performance, future market assessments inclusive of the VOYDEYA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of VOYDEYA sales forecasts, along with factors driving its market.

VOYDEYA Drug Summary

VOYDEYA (Danicopan) is an FDA-approved oral complement factor D inhibitor developed by Alexion (AstraZeneca), indicated as an add-on therapy to ravulizumab or eculizumab for treating extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who experience residual hemolytic anemia despite C5 inhibitor treatment. Administered as 150 mg tablets three times daily (100 mg TID starting dose in severe renal impairment, titratable to 150-200 mg TID), it selectively blocks the alternative complement pathway by preventing factor B cleavage into Ba/Bb fragments, inhibiting C3 convertase formation and downstream opsonization of PNH red blood cells, thereby reducing extravascular macrophage phagocytosis in the spleen/liver. Phase III trials (e.g., VALIANT) demonstrated superiority over placebo, with mean hemoglobin increases of 2.9 g/dL (vs. 0.5 g/dL), reduced fatigue (FACIT-Fatigue +8.0 vs. +1.9), lower absolute reticulocyte counts (-83.8 × 10^9/L vs. -3.5 × 10^9/L), and improved transfusion avoidance; available only via the VOYDEYA REMS program due to infection risks (e.g., meningococcal), with common side effects including headache, nasopharyngitis, diarrhea, pruritus, and elevated liver enzymes. The report provides VOYDEYA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the VOYDEYA Market Report

The report provides insights into:

• A comprehensive product overview including the VOYDEYA MoA, description, dosage and administration, research and development activities in approved indications like Paroxysmal nocturnal haemoglobinuria; as well as potential indications like Chronic urticaria and Dry macular degeneration.
• Elaborated details on VOYDEYA regulatory milestones and other development activities have been provided in VOYDEYA market report.
• The report also highlights VOYDEYA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The VOYDEYA market report also covers the patents information, generic entry and impact on cost cut.
• The VOYDEYA market report contains current and forecasted VOYDEYA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The VOYDEYA market report also features the SWOT analysis with analyst views for VOYDEYA in approved and potential indications.

Methodology

The VOYDEYA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VOYDEYA Analytical Perspective by DelveInsight

• In-depth VOYDEYA Market Assessment

This VOYDEYA sales market forecast report provides a detailed market assessment of VOYDEYA for approved indication like Paroxysmal nocturnal haemoglobinuria; as well as potential indications like Chronic urticaria and Dry macular degeneration in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted VOYDEYA sales data uptil 2034.

• VOYDEYA Clinical Assessment

The VOYDEYA market report provides the clinical trials information of VOYDEYA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

VOYDEYA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

VOYDEYA Market Potential & Revenue Forecast

• Projected market size for the VOYDEYA and its key indications
• Estimated VOYDEYA sales potential (VOYDEYA peak sales forecasts)
• VOYDEYA Pricing strategies and reimbursement landscape

VOYDEYA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• VOYDEYA Market positioning compared to existing treatments
• VOYDEYA Strengths & weaknesses relative to competitors

VOYDEYA Regulatory & Commercial Milestones

• VOYDEYA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

VOYDEYA Clinical Differentiation

• VOYDEYA Efficacy & safety advantages over existing drugs
• VOYDEYA Unique selling points

VOYDEYA Market Report Highlights

• In the coming years, the VOYDEYA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The VOYDEYA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VOYDEYA’s dominance.
• Other emerging products for Paroxysmal nocturnal haemoglobinuria; as well as potential indications like Chronic urticaria and Dry macular degeneration are expected to give tough market competition to VOYDEYA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VOYDEYA in approved and potential indications.
• Analyse VOYDEYA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted VOYDEYA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of VOYDEYA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of VOYDEYA? How strong is VOYDEYA’s clinical and commercial performance?
• What is VOYDEYA’s clinical trial status in each individual indications such as Paroxysmal nocturnal haemoglobinuria; as well as potential indications like Chronic urticaria and Dry macular degeneration and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VOYDEYA Manufacturers?
• What are the key designations that have been granted to VOYDEYA for approved and potential indications? How are they going to impact VOYDEYA’s penetration in various geographies?
• What is the current and forecasted VOYDEYA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of VOYDEYA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to VOYDEYA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is VOYDEYA? What is the duration of therapy and what are the geographical variations in cost per patient?

Show more